Leveraging a proprietary structure-based technology, ADRx utilizes a deep understanding of amyloid protein structure, aggregation, and function to develop small molecule disaggregators and inhibitors targeting misfolded proteins in neurodegenerative diseases. Their drug discovery platform offers a portfolio of drug candidates for Alzheimer's disease, systemic amyloidosis, and ovarian cancer, addressing unmet medical needs in amyloid diseases. ADRx's pipeline includes programs focused on tau, TDP-43, and alpha-synuclein, aiming to provide effective treatments for these challenging conditions.